Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals Announces FUSILEV as Tradename for Levoleucovorin for Injection
Published in Cancer Weekly, July 8th, 2008
Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) announced the selection of FUSILEV(TM) (levoleucovorin) for injection as the trade name for levoleucovorin, the company's proprietary drug which was approved by the FDA on March 7, 2008. FUSILEV(TM) is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. As a result, the Company anticipates FUSILEV(TM) being available to doctors and patients in mid-August 2008.
"We are pleased that patients will soon be able to receive FUSILEV(TM)," said Rajesh C....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-07-08)
More Articles from Cancer Weekly
- Analgesics
In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict - BSD Medical Corp.
ESMO Guideline Working Group Recommends Hyperthermia Therapy as Treatment Option for Soft Tissue Sarcoma Reports BSD Medical - Cancer
CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck - Cancer Gene Therapy
Study data from Xi'an Jiao Tong University, Medical Department provide new insights into cancer gene therapy - Cancer Vaccines
a Shot in the Arm Against Breast Cancer - Cancer Vaccines
Data on cancer vaccines detailed by researchers at National Institutes of Health - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
